ACKB Ackermans & van Haaren NV

Ackermans & van Haaren: First-Half 2025 Results

Ackermans & van Haaren: First-Half 2025 Results

Dear shareholder,

Dear Madam, Dear Sir,



Ackermans & van Haaren publishes today its Half-Year 2025 Results 

Strong results of core participations support the growth of Ackermans & van Haaren’s H1 2025 profit to 273 million euros (+36%)

  • Record half-year results at DEME, Delen Private Bank, Bank Van Breda and SIPEF
  • Significant improvement of results at Nextensa
  • Outlook (strengthened): net profit for the full-year 2025 is expected to increase by at least 15%
  • Positive net cash position of 431 million euros

Please find annexed the full press release.

Best regards

Ackermans & van Haaren

Attachment



EN
29/08/2025

Underlying

ACKBAckermans & van Haaren NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ackermans & van Haaren NV

 PRESS RELEASE
Free
ACKB Ackermans & van...

Ackermans & van Haaren supports MRM Health’s Series B financing round ...

Ackermans & van Haaren supports MRM Health’s Series B financing round of 55 million euros Dear shareholder, Dear Madam, Dear Sir, Ackermans & van Haaren (AvH) supports the Series B financing round totaling 55 million euros of MRM Health, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology. For AvH, this series B financing round involves an additional investment of 3 million euros and brings its total investment in MRM Health to 10.8 million euros and its fully diluted participation to 14.1%. Please find the ...

September 4, 2025 1 EN
 PRESS RELEASE
Free
ACKB Ackermans & van...

Ackermans & van Haaren soutient le tour de financement de série B de 5...

Ackermans & van Haaren soutient le tour de financement de série B de 55 millions d’euros de MRM Health Cher actionnaire, Monsieur, Madame, Ackermans & van Haaren (AvH) soutient le tour de financement de Série B totalisant 55 millions d’euros de MRM Health, une société biopharmaceutique en phase clinique, pionnière dans les thérapeutiques basées sur le microbiome pour les maladies inflammatoires et l’immuno-oncologie. Pour AvH, ce tour de financement de Série B comprend un investissement supplémentaire de 3 millions d'euros, ce qui porte l'investissement total d'AvH dans MRM Health à 10...

September 4, 2025 1 EN
 PRESS RELEASE
Free
ACKB Ackermans & van...

Ackermans & van Haaren ondersteunt de serie B-financieringsronde van 5...

Ackermans & van Haaren ondersteunt de serie B-financieringsronde van 55 miljoen euro van MRM Health Geachte aandeelhouder, Geachte mevrouw, geachte heer, Ackermans & van Haaren (AvH) ondersteunt de serie B-financieringsronde van in totaal 55 miljoen euro van MRM Health, een biofarmaceutisch bedrijf in de klinische fase dat pioniert met therapieën op basis van het microbioom voor inflammatoire aandoeningen en immuun-oncologie. Voor AvH omvat deze serie B-financieringsronde een aanvullende investering van 3 miljoen euro, waarmee de totale investering van AvH in MRM Health op 10,8 miljoen...

September 4, 2025 1 EN
ING Helpdesk
  • ING Helpdesk
ACKB Ackermans & van...
ASRNL ASR Nederland N... ... (+4)

Benelux Morning Notes

AEGON & ASR: placing a 6% stake in ASR, happy family. Events Calendar

ACKB ACKERMANS & VAN HAAREN NV
ASRNL ASR NEDERLAND NV
KIN KINEPOLIS GROUP NV
AGN AEGON N.V.
09/03/25 September 3, 2025 1 EN
Hans D’Haese ... (+2)
  • Hans D’Haese
  • Jason Kalamboussis
ACKB Ackermans & van...

Ackermans & van Haaren/1H25 postview and model update/HOLD

In this note we update our Sum-of-the-Parts valuation model after the 1H25 results publication and related analyst meeting. This note summarises the key topics from the release and updates our earnings forecasts. Last week's release was a clear illustration of Ackermans & van Haaren's (AvH) successful strategy of focusing on a limited number of assets in different sectors of growth that are jointly creating a regular stream of revenues as the main driver for value creation for the group. We have...

ACKB ACKERMANS & VAN HAAREN NV
09/03/25 September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch